151
Participants
Start Date
August 8, 2023
Primary Completion Date
January 8, 2025
Study Completion Date
January 8, 2025
acalabrutinib
patients with CLL who initiated treatment with acalabrutinib over the period between 1st May 2021 and 30th April 2022, according to Italian legislation dlg 219/2006 art.125
Research Site, Torino
Research Site, Torino
Research Site, Torino
Research Site, Torino
Research Site, Cuneo
Research Site, Alessandria
Research Site, Genova
Research Site, Rozzano
Research Site, Milan
Research Site, Milan
Research Site, Monza
Research Site, Varese
Research Site, Crema
Research Site, Padua
Research Site, Ravenna
Research Site, Ancona
Research Site, Pescara
Research Site, Bari
Research Site, San Giovanni Rotondo
Research Site, Foggia
Research Site, Brindisi
Research Site, Tricase
Research Site, Lecce
Research Site, Barletta
Research Site, Napoli
Research Site, Pagani
Research Site, Salerno
Research Site, Campobasso
Research Site, Cosenza
Research Site, Catanzaro
Research Site, Reggio Calabria
Research Site, Catania
Research Site, Messina
Research Site, Frosinone
Research Site, Perugia
Research Site, Roma
Research Site, Roma
Research Site, Roma
Research Site, Roma
Research Site, Roma
Research Site, Viterbo
Lead Sponsor
Yghea
UNKNOWN
AstraZeneca
INDUSTRY